GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Eric Stier sold 2,750 shares of GenMark Diagnostics stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $9.60, for a total value of $26,400.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eric Stier also recently made the following trade(s):

  • On Tuesday, September 5th, Eric Stier sold 311 shares of GenMark Diagnostics stock. The stock was sold at an average price of $9.75, for a total value of $3,032.25.

Shares of GenMark Diagnostics, Inc. (NASDAQ GNMK) traded down 1.04% during mid-day trading on Wednesday, hitting $9.56. The company had a trading volume of 313,922 shares. The company’s market cap is $522.62 million. The firm has a 50-day moving average of $9.53 and a 200-day moving average of $11.66. GenMark Diagnostics, Inc. has a 12 month low of $8.88 and a 12 month high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last released its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The business had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. During the same quarter last year, the company posted ($0.30) earnings per share. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, analysts expect that GenMark Diagnostics, Inc. will post ($1.07) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/genmark-diagnostics-inc-gnmk-svp-eric-stier-sells-2750-shares.html.

Several research analysts have recently commented on GNMK shares. Canaccord Genuity reiterated a “buy” rating and set a $17.00 price target on shares of GenMark Diagnostics in a report on Monday, June 12th. Needham & Company LLC lifted their price target on GenMark Diagnostics from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, June 13th. BidaskClub downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Cowen and Company reissued an “outperform” rating and set a $17.00 price objective on shares of GenMark Diagnostics in a research report on Wednesday, August 2nd. Finally, BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of GenMark Diagnostics in a research report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $14.40.

Institutional investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd purchased a new position in shares of GenMark Diagnostics in the 2nd quarter worth about $126,000. Legal & General Group Plc raised its holdings in shares of GenMark Diagnostics by 2.1% in the 2nd quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock worth $137,000 after purchasing an additional 240 shares during the period. Susquehanna International Group LLP purchased a new position in shares of GenMark Diagnostics in the 2nd quarter worth about $137,000. Airain ltd purchased a new position in shares of GenMark Diagnostics in the 1st quarter worth about $159,000. Finally, Quantitative Systematic Strategies LLC raised its holdings in shares of GenMark Diagnostics by 18.4% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 2,047 shares during the period.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.